Table 3 Liver fibrosis progression, decompensation and end stage liver disease outcomes
Study | Intervention | Outcome | Follow-up duration | Effect estimate | Statistically significant?a | Adjustments |
|---|---|---|---|---|---|---|
End-stage liver disease (ESLD) and decompensation events | ||||||
 Giron-Gonzalez (2007) [29] | cART | Decompensationj | Median 20 months (IQR 12 to 28) | HR 0.376 (95 % CI 0.161 to 0.883) | Yes. Favours treatment | Liver disease severity |
 Giron-Gonzalez (2007) [29] | cART | Decompensationj | Median 20 months (IQR 12 to 28) | NR | No | None |
 Pineda (2009) [32] | cART | Decompensation | Mean 36 months (SD 27), range 1 to 131 months | RR 1.06 (95 % CI 0.30 to 3.71) | No | None |
 Ragni (2009) [27] | cART & ARV monotherapy | ESLD | NR (up to 35 years from HCV infection) | RR 1.00 (95 % CI 0.37 to 2.71) | No | None |
 Ragni (2009) [27] | cART vs. ARV monotherapy & no ARVb | Time to ESLD | NR (up to 35 years from HCV infection) | HR 3.14 (95 % CI 1.27 to 7.08) (30.3 vs. 20.0 Years) | Yes. Favours treatment | Multivariate (covariates NR) |
Liver fibrosis progression (dichotomous) | ||||||
 Macias (2006) [25] | cART with PI | Liver fibrosis progressiond | Median 1.6 to 7 years | OR 0.4 (95 % CI 0.2 to 0.7) | Yes. Favours treatment | Age at infection, CD4 count |
 Macias (2006) [25] | cART with PI switched to efavirenz | Liver fibrosis progressiond | Median 1.6 to 7 years | OR 0.3 (95 % CI 0.1 to 0.7) | Yes. Favours treatment | Age at infection, CD4 count |
 Schiavini (2006) [28] | cART and ARV monotherapy | Liver fibrosis progressione | Median 54 months (IQR 50 to 86) | OR 2.5 (95 % CI 0.64 to 9.65) | No | None |
 Macias (2009) [24] | cART and ARV monotherapy | Liver fibrosis progressionh | 3 years | OR 0.94 (95 % CI 0.67 to 1.33) | No | Multivariatek |
 Mehta (2005) [30] | ARV monotherapy | Advanced fibrosis or cirrhosisc | Median 5 years (IQR 2.9 to 7.5) | OR 0.61 (95 % CI 0.18 to 2) | No | None |
 Mehta (2005) [30] | cART | Advanced fibrosis or cirrhosisc | Median 5 years (IQR 2.9 to 7.5) | OR 0.92 (95 % CI 0.48 to 1.8) | No | None |
 Sanmartin (2014) [33] | cART | Liver fibrosis progressioni | Median 7.8 years (IQR 5.5 to 10.0) | HR 1.94 (95 % CI 0.46 to 8.13) | No | None |
Liver fibrosis progression (continuous) | ||||||
 Macias (2006) [25] | cART with: NVP; or efavirenz; or with PI switched to NVP | Fibrosis progression ratef | Median 1.6 to 7 years | Median rate 0.087 to 0.115 | No | None |
 Macias (2006) [25] | cART with zidovudine/lamivudine, or with stavudine/lamivudine | Fibrosis progression ratef | Median 1.6 to 7 years | Median rate 0.107 and 0.112 | Yes. Favours treatment | None |
 Mariné-Barjoan (2004) [35] | cART | Fibrosis progression ratef | Median 19 to 20 years | MD −0.06 (95 % CI −0.14 to 0.01) | No | None |
 Reiberger (2010) [36] | cART | Fibrosis progression ratef | NR | MD 0.01 (95 % CI −0.01 to 0.04) | No | None |
 Reiberger (2010) [36] | cART | Time to cirrhosisg from initial HCV exposure | NR | MD −1.00 (95 % CI −7.26 to 5.26) | No | None |